According to a Biospace report, the U.S. Food and Drug Administration (FDA) has granted Priority Review for crofelemer 125 mg tablets for the control and symptomatic relief of diarrhoea in patients with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) on anti-retroviral therapy.